NCT03940404

Anlotinib Therapy in Patients With Advanced Lung Cancer.

Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: First People's Hospital of Hangzhou · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world. Subjects of the study: advanced Lung cancer. Methods of the study: This is a real world, prospective, Non-Interventional, Follow-up registration study. Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle. End point: Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).

Conditions

• Lung Neoplasms

Interventions

Type	Name	Description
DRUG	Anlotinib Hydrochloride	Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.

Timeline

• Start date: 2019-05-01
• Primary completion: 2020-05-01
• Completion: 2020-12-01
• First posted: 2019-05-07
• Last updated: 2019-05-07

Locations

1 site across 1 country: China